Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD
不适用
已完成
NCT05612217
| 适应症 | Chronic Venous Disease, CVD |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Servier Russia |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 433 人 |
|---|
| 干预（药物） | to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD |
|---|
| 开始日期 | 2022年12月1日 |
|---|
| 完成日期 | 2023年6月1日 |
|---|
| 结果公布日 | 2024年9月25日 |
|---|
摘要
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD.
1 month · percentage of of positive cases
| Patients With CVD | 75.19 percentage of of positive cases |
|---|
Evaluation of Specificity (Sp) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD
1 month · percentage of negative cases
| Patients With CVD | 86.51 percentage of negative cases |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。